PoC clinical study of ZPL-3893787 on pruritus and inflammation in atopic dermatitis

ZPL-3893787对特应性皮炎瘙痒和炎症的PoC临床研究

• 批准号: 101871
• 金额: $ 216.35万
• 依托单位: ZIARCO PHARMA LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101871
• 关键词: PoC; clinical; study; ZPL; 3893787

Ziarco Pharma Limited, of Canterbury, Kent is developing ZPL-3893787, a novel oral treatment for the itch and inflammation associated with chronic pruritus (CP) - defined as an undesirable condition that stimulates scratching, persisting for at least 6 weeks. It affects all ages, from young infants through to the elderly. CP can result in disturbed/lack of sleep, mood changes and a general increase in other illnesses for sufferers. ZPL-3893787 has been studied in over 50 healthly adult volunteers so far in two different countries. Financial help from the UK Government's Technology Strategy Board will allow Ziarco to test ZPL-3893787 for relieving itch and inflammation in atopic dermatitis (ezcema) patients. Itch and inflammation are present in many diseases, and if proved successful, ZPL-389 may have the chance to treat millions of patients worldwide, from the young through to the elderly.

肯特郡坎特伯雷的Ziarco Pharma有限公司正在开发ZPL-3893787，这是一种新的口服药物，用于治疗与慢性瘙痒(CP)相关的瘙痒和炎症-慢性瘙痒(CP)是一种刺激抓挠的不良条件，持续至少6周。它影响所有年龄段的人，从幼儿到老年人。CP可导致患者受到干扰/睡眠不足、情绪变化和其他疾病的普遍增加。到目前为止，ZPL-3893787已经在两个不同国家的50多名健康成年志愿者中进行了研究。英国政府技术战略委员会的财政援助将允许Ziarco测试ZPL-3893787，用于缓解特应性皮炎(Ezcema)患者的瘙痒和炎症。瘙痒和炎症存在于许多疾病中，如果被证明成功，ZPL-389可能有机会治疗全球数百万患者，从年轻人到老年人。